mV25 – Momentum to Move

Please click here to order this product direct from Dr Shiva.

  • This product is shipped direct from Dr Shiva in Boston USA and the link above will redirect you to the shopping cart on VAShiva.com
  • We are an affiliate for VA Shiva Products.
  • The prices on VAShiva.com are recommended retail in US dollars.

Ingredients: Please refer to gallery photo

Directions: Take two (2) capsules to help reduce discomfort and normal swelling due to daily exercise and normal activity.† Dosage can be increased to 6 capsules daily or as directed by your health care provider.

mV25™ was formulated using the CytoSolve® computational systems biology platform – a technology for Precision and Personalized Medicine – invented by Dr.SHIVA during his doctoral research at MIT. This formulation results from integrating thousands of peer-reviewed scientific papers across 4 decades in 68 research institutions and computing trillions of potential combinations of biochemical reactions to discover an optimal synergy of compounds that downregulate the biomarkers of discomfort and normal swelling.†

CytoSolve® OPTIMIZEDTM means this formula has been optimized to maximize efficacy and bioavailability while minimizing toxicity based on current research curated by CytoSolve®.† As the science advances, so will this formulation. This is our promise.

†These statement have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

CYTOSOLVE CASE STUDY: VASHIVA, LLC.

  • Joint pain is the most prominent and disabling symptom of arthritis. Arthritic pain is associated with inferior functional outcomes and reduced quality of life compared to other chronic conditions. An integrative in silico – computational model –  of joint health is developed to predict the effect of phytonutrients on five biomarkers of joint health, namely, PGE-2, TRPV1, CGRP, COX-2 and reactive oxygen species. A formulation of two bioflavonoids was identified, tested, and optimized for its efficacy on the biomarkers of joint health. The results from the CytoSolve in silico modeling demonstrate that ingredients in this formulation synergistically alleviate joint pain by lowering PGE-2, TRPV1, CGRP, COX-2 and reactive oxygen species. The formulation is currently marketed under the brand name mV25.